Trevena is committed to the ethical promotion of OLINVYK. Trevena’s goal is NOT to increase opioid usage; rather, Trevena is asking prescribers to consider OLINVYK as a differentiated alternative versus conventional IV opioids when an IV opioid is necessary to manage the patient’s acute pain.
* Onset of pain relief was evaluated in a Phase 2, fixed-dose bunionectomy trial in which 192 patients were treated with OLINVYK IV every 3 hours, placebo IV, or morphine IV every 4 hours. Time to onset of analgesia was determined using the 2-stopwatch method, for which patients were given 2 stopwatches and instructed to stop the first for perceptible improvement in pain and the second for meaningful improvement in pain.5
† OLINVYK was studied in an open-label safety study in patients with moderate to severe acute postoperative pain (N=768), including obese patients (46%), elderly patients (32%), and patients with comorbidities (all patients had ≥1 comorbid condition), administered using clinician-administered bolus dosing, PCA, or a combination of the two.2